- Home
- / InVivo Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
InVivo Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.4
2024-04-15
Market Capitalization
$995.9 K
2024-04-15
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 4.6M | 6.4M | 8.5M | 7.6M | 12.3M | 11.5M | 13.5M | 7.8M | 5.9M | 5.2M | 5.5M | 5.4M |
| Operating expense total | 8.7M | 12.8M | 19.0M | 17.8M | 22.4M | 24.1M | 24.6M | 12.8M | 11.5M | 9.1M | 10.7M | |
| EBIT | (8.7M) | (12.8M) | (19.0M) | (17.8M) | (22.4M) | (24.1M) | (24.6M) | (12.8M) | (11.5M) | (9.1M) | (9.9M) | (10.6M) |
| Interest income | 8.8K | 35.2K | 15.3K | 5.0K | 60.0K | 187.0K | 189.0K | 79.0K | 4.0K | 2.0K | ||
| Interest expense | 12.7K | 71.7K | 206.0K | 254.0K | 19.0K | 3.0K | 151.0K | |||||
| Net Income | (34.7M) | 4.7M | (38.8M) | (18.3M) | (33.3M) | (23.4M) | (26.7M) | (23.4M) | (11.8M) | (9.1M) | (9.9M) | (10.5M) |
| EPS | 0.8 | 1.3 | 0.8 | (6.8) |